Another class encountered in trials was represented by dementia therapeutic agents acting on neuronal acetylcholine receptor subunit alpha-4, neuronal acetylcholine receptor subunit beta-2, neuronal acetylcholine receptor subunit alpha-7 (gene names: CHRNA4, CHRNB2, CHRNA7, respectively). The gene discussed is CHRNB2; the disease is dementia.